Oxcarbazepine in migraine headache

Silberstein, SD; Saper, Joel R.; Berenson, Frank; Somogyi, Monique; McCague, Kevin; D’Souza, Joseph

doi:10.1212/01.wnl.0000297551.27191.70

Cited by 73 publications

(36 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…33−36 Notably, even within class, some drugs are effective (e.g., antiepileptics such as valproate and topiramate) 13,37,38 while others (e.g., oxcarbazepine) are not. 39 Moreover, many of these treatments are associated with troublesome side effects, including sedation, difficulty in thinking, and weight gain, and are not well tolerated in many patients. Because many patients do not respond to current prophylactic medications, a strong medical need for discovery of new therapeutics exists.…”

Section: Chronic Migraine and Medication Overuse Headachementioning

confidence: 99%

Targeting TRP Channels For Novel Migraine Therapeutics

Dussor

Yan

Xie

et al. 2014

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Migraine is increasingly understood to be a disorder of the brain. In susceptible individuals, a variety of “triggers” may influence altered central excitability, resulting in the activation and sensitization of trigeminal nociceptive afferents surrounding blood vessels (i.e., the trigeminovascular system), leading to migraine pain. Transient receptor potential (TRP) channels are expressed in a subset of dural afferents, including those containing calcitonin gene related peptide (CGRP). Activation of TRP channels promotes excitation of nociceptive afferent fibers and potentially lead to pain. In addition to pain, allodynia to mechanical and cold stimuli can result from sensitization of both peripheral afferents and of central pain pathways. TRP channels respond to a variety of endogenous conditions including chemical mediators and low pH. These channels can be activated by exogenous stimuli including a wide range of chemical and environmental irritants, some of which have been demonstrated to trigger migraine in humans. Activation of TRP channels can elicit CGRP release, and blocking the effects of CGRP through receptor antagonism or antibody strategies has been demonstrated to be effective in the treatment of migraine. Identification of approaches that can prevent activation of TRP channels provides an additional novel strategy for discovery of migraine therapeutics.

show abstract

Section: Chronic Migraine and Medication Overuse Headachementioning

confidence: 99%

Targeting TRP Channels For Novel Migraine Therapeutics

Dussor

Yan

Xie

et al. 2014

ACS Chem. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Oxcarbazepine was not effective for migraine prophylaxis in a placebo-controlled trial. 28 Lamotrigine was less efficacious for migraine than topiramate in a small double-blind placebo-controlled trial and only marginally better than placebo, 29 confirming the general clinical impression that lamotrigine has low efficacy for migraine.…”

Section: Unique Patient and Antiepileptic Drug Characteristicsmentioning

confidence: 84%

Choosing Among Antiepileptic Drugs

Fountain¹

2010

CONTINUUM: Lifelong Learning in Neurology

View full text Add to dashboard Cite

Selecting an antiepileptic drug (AED) for treatment of seizures is daunting because there are now 20 from which to choose. Following simple principles allows a systematic approach to drug selection. Efficacy studies provide limited information. For initial monotherapy of partial seizures, high-level evidence exists for the efficacy of lamotrigine, carbamazepine, oxcarbazepine, and topiramate. For initial monotherapy of generalized seizures, high-level evidence is available for valproate, lamotrigine, topiramate, and oxcarbazepine. For initial monotherapy of absence seizures, high-level evidence exists for valproate, lamotrigine, and ethosaximide. All second-generation AEDs have efficacy as adjunctive therapy for partial seizures. AEDs are often useful for comorbid conditions or have properties that should be avoided in some groups. Thus, AEDs should usually be selected on the basis of comorbid conditions, including depression, migraine, chronic pain, obesity, and nephrolithiasis, or patient characteristics, especially for women of childbearing potential and older adults.

show abstract

“…Carrazana found that the evidence supporting the use of OXC for trigeminal neuralgia is strong [9,10]. The use of OXC for other indications such as painful diabetic neuropathy, post-herpetic neuralgia, painful paroxysmal symptoms in multiple sclerosis, tremor, and migraine has already been investigated with a poor-moderate evidence level [5,[11][12][13][14]. In this study, the use of OXC in trigeminal neuralgia is categorized as offlabel use because the distribution license in Indonesia does not include an indication for OXC in trigeminal neuralgia.…”

Section: Discussionmentioning

confidence: 99%

A Retrospective Study: The Off-Label Use of Anticonvulsants at a Private Hospital in Indonesia

Rahajeng

Ikawati

Andayani

et al. 2018

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: Anticonvulsant is one class of drugs often used off-label. This study was conducted to investigate the prevalence and the indication of the off-label use of anticonvulsants in a private hospital in Java, Indonesia. Methods:This was an observational study with a retrospective data collection in a private hospital in Java. Data were obtained on the prescription of anticonvulsants. Indications of the use of anticonvulsants were obtained from the medical records of patients who were prescribed anticonvulsants. The off-label use of anticonvulsants was defined a prescribing of medication outside the indication approved by The National Agency of Drug and Food Control Indonesia (NA-DFC). The use off-label of anticonvulsants was calculated by descriptive analysis and presented as a percentage.Results: It showed that in one year there were 5,310 for 1,316 patients: of this 462 patients (35.11%) were for an off-label use. The anticonvulsants used off-label were oxcarbazepine 67.27% (37/55), carbamazepine 46.15% (54/117), pregabalin45.45% (60/132), phenytoin37.62% (225/598), valproate 25.34% (37/109), and gabapentin 18.28% (49/219). The highest off-label use of anticonvulsants was found in neurological and psychiatric disorders 67.32% (n=311), and on 97.19% of them were not supported by strong clinical evidence. Conclusion:The off-label use of anticonvulsants occurred in one-third of patients receiving prescriptions of anticonvulsants, even though for most of them there was a lack of evidence. More attention must be paid to the efficacy and risk of side effects of the drug used.

show abstract

Oxcarbazepine in migraine headache

Abstract: Overall, oxcarbazepine was safe and well tolerated; however, oxcarbazepine did not show efficacy in the prophylactic treatment of migraine headaches.

Cited by 73 publications

References 16 publications

Targeting TRP Channels For Novel Migraine Therapeutics

Targeting TRP Channels For Novel Migraine Therapeutics

Choosing Among Antiepileptic Drugs

A Retrospective Study: The Off-Label Use of Anticonvulsants at a Private Hospital in Indonesia

Contact Info

Product

Resources

About